FDA rejects Summit's ivonescimab, finding no significant survival benefit
Summit Therapeutics said Sunday it received a complete response letter on the lung cancer drug it is developing with Akeso. Its Nasdaq shares fell around 13 percent Monday morning.
- The FDA refused Summit’s application for ivonescimab in EGFR-mutated non-small cell lung cancer.
- Regulators said overall survival in the Phase III HARMONi trial was not statistically significant, a bar they had set for approval.
- Median time before the cancer worsened was 6.8 months on ivonescimab versus 4.4 months on placebo.